Danon Disease

The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers sponsored genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. The test is billed to insurance first; when a claim is denied or the patient is uninsured, the program's sponsor covers the cost of testing. Testing must be ordered by a qualified healthcare provider.

The Mission: Genome – Danon Disease Program offers no-charge Invitae testing for US-based patients with clinical suspicion of Danon disease. Testing includes LAMP2 as part of the Invitae Arrhythmia and Cardiomyopathy Panel. Eligible patients also receive no-charge post-test genetic counseling to support result interpretation and follow-up care.

The Mission: Genome – Danon Disease Program offers no-charge genetic testing through Ambry Genetics for US-based patients age 40 or younger with a clinical suspicion of Danon disease or an inherited cardiomyopathy. Testing uses Ambry's CardioNext®, a 92-gene cardiomyopathy and arrhythmia panel that includes LAMP2. The program is sponsored by Rocket Pharma and includes no-charge genetic counseling for eligible patients and families.